PURPOSE: To evaluate the efficacy of 9-amino [20s] camptothecin (9-AC) given before radiation therapy to patients with newly diagnosed glioblastoma multiforme (GBM). METHODS: Eligible patients had newly diagnosed GBM who had residual measurable contrast-enhancing tumor. The trial was a phase 2 trial of 9-AC at 1100 microg/m2 /24 h infused over 72 h every two weeks for up to six cycles in patients with newly diagnosed GBM before radiation therapy. RESULTS: Fourteen patients entered the study and all were evaluable. All of the patients had progressive disease by imaging criteria after at least two cycles of 9-AC (1 month). The median overall survival was 7.5 months (range 1.5-18 months). The most common adverse event was transient lymphopenia (grade 3-4). One patient developed grade 4 neutropenic fever that resolved after three days of diagnosis. CONCLUSIONS: 9-AC lacks activity against glioblastoma multiforme (GBM). Further studies looking at the efficacy of 9-AC in GBM may be futile.
PURPOSE: To evaluate the efficacy of 9-amino [20s] camptothecin (9-AC) given before radiation therapy to patients with newly diagnosed glioblastoma multiforme (GBM). METHODS: Eligible patients had newly diagnosed GBM who had residual measurable contrast-enhancing tumor. The trial was a phase 2 trial of 9-AC at 1100 microg/m2 /24 h infused over 72 h every two weeks for up to six cycles in patients with newly diagnosed GBM before radiation therapy. RESULTS: Fourteen patients entered the study and all were evaluable. All of the patients had progressive disease by imaging criteria after at least two cycles of 9-AC (1 month). The median overall survival was 7.5 months (range 1.5-18 months). The most common adverse event was transient lymphopenia (grade 3-4). One patient developed grade 4 neutropenic fever that resolved after three days of diagnosis. CONCLUSIONS: 9-AC lacks activity against glioblastoma multiforme (GBM). Further studies looking at the efficacy of 9-AC in GBM may be futile.
Authors: H S Friedman; T Kerby; S Fields; J E Zilisch; D Graden; R E McLendon; P J Houghton; S Arbuck; I Cokgor; A H Friedman Journal: Cancer Date: 1999-03-01 Impact factor: 6.860
Authors: H S Friedman; W P Petros; A H Friedman; L J Schaaf; T Kerby; J Lawyer; M Parry; P J Houghton; S Lovell; K Rasheed; T Cloughsey; E S Stewart; O M Colvin; J M Provenzale; R E McLendon; D D Bigner; I Cokgor; M Haglund; J Rich; D Ashley; J Malczyn; G L Elfring; L L Miller Journal: J Clin Oncol Date: 1999-05 Impact factor: 44.544
Authors: P A Burch; A M Bernath; T L Cascino; B W Scheithauer; P Novotny; S Nair; J C Buckner; D M Pfeifle; J W Kugler; L K Tschetter Journal: Invest New Drugs Date: 2000-08 Impact factor: 3.850
Authors: W Dahut; N Harold; C Takimoto; C Allegra; A Chen; J M Hamilton; S Arbuck; M Sorensen; F Grollman; H Nakashima; R Lieberman; M Liang; W Corse; J Grem Journal: J Clin Oncol Date: 1996-04 Impact factor: 44.544
Authors: Kristine R Crews; Clinton F Stewart; Dana Jones-Wallace; Stephen J Thompson; Peter J Houghton; Richard L Heideman; Maryam Fouladi; Daniel C Bowers; Murali M Chintagumpala; Amar Gajjar Journal: Clin Cancer Res Date: 2002-07 Impact factor: 12.531
Authors: E Rubin; V Wood; A Bharti; D Trites; C Lynch; S Hurwitz; S Bartel; S Levy; A Rosowsky; D Toppmeyer Journal: Clin Cancer Res Date: 1995-03 Impact factor: 12.531